Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,055,281 papers from all fields of science
Search
Sign In
Create Free Account
EGFR Antibody
Known as:
ERBB1 Antibody
, Anti-HER1
, HER1 Antibody
Expand
Any immunoglobulin that recognizes epidermal growth factor receptor protein.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Immune System Processes
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Should Anti-EGFR Agents Be Used in Right-Sided RAS Wild-type Advanced Colorectal Cancer?
L. Triest
,
C. Debeuckelaere
,
+6 authors
M. Peeters
Current Colorectal Cancer Reports
2019
Corpus ID: 195302050
Purpose of ReviewColorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages of…
Expand
2014
2014
Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin-and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and / or Metastatic Colorectal Cancer : Evaluation of Efficacy and…
H. Soeda
,
H. Shimodaira
,
+11 authors
C. Ishioka
2014
Corpus ID: 33563188
Background: Mutations in the KRAS gene have been identified as negative predictors of response to anti-epidermal growth factor…
Expand
2011
2011
[99mTc(CO)3]+-Labeled anti-epidermal growth factor receptor (HER2) affibody ZHER2:342 with a tri-(histidine-glutamate) peptide tag (HE)3 on the N-terminal
A. Chopra
2011
Corpus ID: 89536196
2011
2011
[Table, 111In-Labeled DOTA-conjugated 6-aminohexanoic linker-containing variant of anti-epidermal growth factor receptor 2 Affibody ZHER2:342 (ABY-003)].
A. Chopra
2011
Corpus ID: 91881809
2011
2011
[99mTc(CO)3]+-Labeled anti-epidermal growth factor receptor (HER2) affibody ZHER2:342 with a hexa-histidine tag (H6) on the C-terminal
A. Chopra
2011
Corpus ID: 91923292
2010
2010
Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC).
A. Sood
,
D. McClain
,
+6 authors
S. Goel
2010
Corpus ID: 70885373
3567 Background: EGFR directed therapy is limited by mutations in KRAS or BRAF; however, the search for other predictive…
Expand
2006
2006
Cetuximab Therapy in Colorectal Cancer Mutation Status Is Predictive of Response to KRAS Updated
A. Lièvre
,
J. Bachet
,
+10 authors
P. Laurent-Puig
2006
Corpus ID: 10045719
The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer…
Expand
2005
2005
From XenoMouse® Technology to Panitumumab (ABX-EGF)
Xiao-Dong Yang
,
L. Roskos
,
C. Davis
,
G. Schwab
2005
Corpus ID: 81258176
Recent success of antibody therapeutics in oncology has revived a keen interest in the development of monoclonal antibodies (mAbs…
Expand
1998
1998
Cooperative inhibition of human renal cancer cell growth by treatment with anti-epidermal growth factor receptor monoclonal antibody and a mixed backbone antisense oligonucleotide targeting type I…
F. Ciardiello
,
R. Caputo
,
+7 authors
G. Tortora
1998
Corpus ID: 103981186
1989
1989
Growth inhibition of human nasopharyngeal carcinoma in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
E. Guan
,
Ting-Dong Zhou
,
+5 authors
Minglun Zhao
The International Journal Of Cell Cloning
1989
Corpus ID: 25516415
Monoclonal antibodies (MoAbs) were developed against epidermal growth factor (EGF) receptor on the human epidermoid carcinoma…
Expand